Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:6354
Name CLL/SLL
Definition A chronic lymphocytic leukemia that is characterized by the presence of immature lymphocytes in the blood and bone marrow and/or in the lymph nodes.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia chronic lymphocytic leukemia CLL/SLL

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Ibrutinib CLL/SLL not applicable detail...
Unknown unknown Venetoclax CLL/SLL not applicable detail...
Unknown unknown Idelalisib CLL/SLL not applicable detail...
Unknown unknown Obinutuzumab + Venetoclax CLL/SLL not applicable detail...
Unknown unknown Zanubrutinib CLL/SLL not applicable detail...
Unknown unknown Ibrutinib + Rituximab CLL/SLL not applicable detail...
Unknown unknown Orelabrutinib CLL/SLL not applicable detail...
Unknown unknown ME-401 CLL/SLL not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Recruiting
NCT01125176 Phase II Lenalidomide + Rituximab + Thalidomide Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL Active, not recruiting
NCT01253460 Phase II Cyclophosphamide Rituximab + Sapacitabine Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Terminated
NCT01353625 Phase I CC-115 Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. Active, not recruiting
NCT01796171 Phase Ib/II Lilotomab Betalutin Rituximab A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01) Recruiting
NCT01804686 Phase III Ibrutinib A Long-term Extension Study of PCI-32765 (Ibrutinib) Enrolling by invitation
NCT01811368 Phase II anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Recruiting
NCT01886859 Phase I Ibrutinib + Lenalidomide Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting
NCT01976585 Phase Ib/II CDX-301 + Poly ICLC In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy Recruiting
NCT01994382 Phase I Cerdulatinib Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma Active, not recruiting
NCT02000934 Phase I Mivavotinib A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies Active, not recruiting
NCT02005289 Phase II Lenalidomide + Tafasitamab-cxix Ibrutinib + Tafasitamab-cxix Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL Active, not recruiting
NCT02006485 Phase I Ublituximab + Umbralisib Ibrutinib Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies Completed
NCT02007044 Phase II Ibrutinib Ibrutinib + Rituximab Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia Active, not recruiting
NCT02029443 Phase Ib/II Acalabrutinib ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia Active, not recruiting
NCT02160015 Phase I Ibrutinib + Lenalidomide + Rituximab Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery Active, not recruiting
NCT02254772 Phase Ib/II Ipilimumab + SD-101 TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma Completed
NCT02266147 Phase Ib/II SD-101 Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma Completed
NCT02296918 Phase I Acalabrutinib + Obinutuzumab ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL Active, not recruiting
NCT02329847 Phase Ib/II Ibrutinib + Nivolumab Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies Active, not recruiting
NCT02337829 Phase II Acalabrutinib ACP-196 in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL Active, not recruiting
NCT02339922 Phase II Ixazomib + Rituximab Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma Active, not recruiting
NCT02381080 Phase I Erythromycin + Ibrutinib + Voriconazole Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy Completed
NCT02384954 Phase Ib/II ALT-803 + Rituximab ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab Active, not recruiting
NCT02406742 Phase Ib/II Obinutuzumab Rituximab Ibrutinib CC-122 A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE) Active, not recruiting
NCT02420912 Phase II Ibrutinib + Nivolumab Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL) Active, not recruiting
NCT02514083 Phase II Fludarabine + Ibrutinib A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Active, not recruiting
NCT02518555 Phase II Ibrutinib Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting
NCT02529813 Phase I Cyclophosphamide + Fludarabine + Tisagenlecleucel CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Active, not recruiting
NCT02556931 Phase II Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Active, not recruiting
NCT02576275 Phase III Bendamustine + Rituximab Duvelisib A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) Withdrawn
NCT02614508 Phase I Buparlisib + Ibrutinib Buparlisib + Ofatumumab Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Terminated
NCT02626455 Phase III Vincristine Sulfate Prednisone Aldoxorubicin + Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Copanlisib Bendamustine + Rituximab Rituximab Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) Active, not recruiting
NCT02629809 Phase II Cyclophosphamide + Fludarabine + Ibrutinib + Obinutuzumab Ibrutinib + Obinutuzumab Ibrutinib Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia Recruiting
NCT02639910 Phase II Tafasitamab-cxix + Venetoclax Idelalisib + Tafasitamab-cxix Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS) Active, not recruiting
NCT02640209 Phase I CART19 cells Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) Terminated
NCT02640833 Phase I Duvelisib + Venetoclax A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor Withdrawn
NCT02662296 Phase II Idelalisib Ibrutinib Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant Withdrawn
NCT02677948 Phase Ib/II Ibrutinib + Pacritinib Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Withdrawn
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting
NCT02727803 Phase II anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma Recruiting
NCT02756897 Phase II Ibrutinib + Venetoclax Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) Active, not recruiting
NCT02787369 Phase I Idelalisib + Ricolinostat Ibrutinib + Ricolinostat ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL Active, not recruiting
NCT02846623 Phase II Atezolizumab + Obinutuzumab + Venetoclax Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome Recruiting
NCT02867618 Phase Ib/II Carfilzomib + Umbralisib Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma Recruiting
NCT02900716 Phase I DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas Recruiting
NCT02910583 Phase II Ibrutinib Ibrutinib + Venetoclax Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma Active, not recruiting
NCT02914938 Phase I ME-401 ME-401 + Rituximab A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Recruiting
NCT02924402 Phase I XmAb13676 Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies Recruiting
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Suspended
NCT02960646 Phase I Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting
NCT03010358 Phase Ib/II Entospletinib + Obinutuzumab Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Active, not recruiting
NCT03088878 Phase Ib/II Cirmtuzumab Cirmtuzumab + Ibrutinib Ibrutinib A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Recruiting
NCT03133221 Phase II Idelalisib 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Recruiting
NCT03162536 Phase I ARQ 531 Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies Recruiting
NCT03204188 Phase II Fludarabine + Ibrutinib + Pembrolizumab Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recruiting
NCT03218683 Phase I AZD5991 Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. Active, not recruiting
NCT03331198 Phase Ib/II JCAR017 Ibrutinib + JCAR017 Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Recruiting
NCT03336333 Phase III Zanubrutinib Bendamustine + Rituximab A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL Recruiting
NCT03370185 Phase II Duvelisib Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma Suspended
NCT03379493 Phase I Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma Terminated
NCT03406156 Phase III Bendamustine + Obinutuzumab Obinutuzumab + Venetoclax Bendamustine A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy Active, not recruiting
NCT03422393 Phase I Ibrutinib + Venetoclax Venetoclax Venetoclax With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib Recruiting
NCT03454165 Phase I BNC105P + Ibrutinib A Study of BNC105P Combined With Ibrutinib Recruiting
NCT03462719 Phase III Chlorambucil + Obinutuzumab Ibrutinib + Venetoclax A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Active, not recruiting
NCT03479268 Phase I Ibrutinib + MLN4924 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma Recruiting
NCT03492125 Phase I MS-553 A Study Of The Selective PKC-beta Inhibitor MS- 553 Recruiting
NCT03498612 Phase II Pembrolizumab Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases Recruiting
NCT03516617 Phase II Acalabrutinib Acalabrutinib + Obinutuzumab Acalabrutinib With or Without Obinutuzumab in Treating Participants With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting
NCT03534323 Phase Ib/II Duvelisib + Venetoclax Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL Recruiting
NCT03547115 Phase I Voruciclib A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies Recruiting
NCT03557619 Phase I Ethinylestradiol + Levonorgestrel + Venetoclax A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Subjects With Different Hematological Malignancies Recruiting
NCT03572634 Phase Ib/II Dubermatinib Dubermatinib + Ibrutinib Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL Terminated
NCT03579888 Phase I CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells + Cyclophosphamide + Fludarabine CD19-Specific T Cells Post AlloSCT Recruiting
NCT03580928 Phase II Acalabrutinib + Obinutuzumab + Venetoclax Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL (AVO) Recruiting
NCT03701282 Phase III Ibrutinib + Obinutuzumab Ibrutinib + Obinutuzumab + Venetoclax Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia Recruiting
NCT03711578 Phase II Tenalisib Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) Active, not recruiting
NCT03734016 Phase III Ibrutinib Zanubrutinib A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Recruiting
NCT03740529 Phase Ib/II Cyclophosphamide + Doxorubicin + LOXO-305 + Prednisone + Rituximab + Vincristine Sulfate LOXO-305 + Rituximab + Venetoclax LOXO-305 + Venetoclax LOXO-305 A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Recruiting
NCT03759184 Phase I Obinutuzumab + rhIL-15 Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia Recruiting
NCT03779113 Phase Ib/II HMPL-523 An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma Recruiting
NCT03786926 Phase Ib/II HMPL-689 Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas Recruiting
NCT03788291 Phase II Acalabrutinib + Rituximab Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Recruiting
NCT03824483 Phase II Obinutuzumab + Venetoclax + Zanubrutinib Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) Recruiting
NCT03828448 Phase II Ublituximab + Umbralisib Study to Assess Umbralisib Plus Ublituximab in Patients With Treatment Naive Follicular Lymphoma Recruiting
NCT03884972 Phase I Trabectedin + Venetoclax Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor Withdrawn
NCT03893682 Phase I CG-806 A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas Recruiting
NCT03960840 Phase I Ibrutinib + YTB323 YTB323 CD19-specific CAR-T Cells in CLL/SLL and DLBCL Recruiting
NCT03961672 Phase II Duvelisib Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting
NCT04007029 Phase I Tocilizumab Anti-CD19/CD20 CAR T cells + Cyclophosphamide + Fludarabine Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Recruiting
NCT04014205 Phase I Orelabrutinib A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies Recruiting
NCT04038359 Phase II Duvelisib A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO) Recruiting
NCT04116437 Phase II Zanubrutinib A Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment With Ibrutinib Recruiting
NCT04136275 Phase I Anti-CD37 CAR T cells CAR-37 T Cells In Hematologic Malignancies Recruiting
NCT04155840 Phase II Bendamustine + Copanlisib + Rituximab Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting
NCT04160195 Phase I Cyclophosphamide + Fludarabine Anti-CD19/CD20 CAR T cells T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma Suspended
NCT04169737 Phase II Acalabrutinib + Obinutuzumab + Venetoclax Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Not yet recruiting
NCT04209621 Phase II Duvelisib + Ibrutinib Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recruiting
NCT04230304 Phase II Daratumumab + Ibrutinib Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study Not yet recruiting
NCT04419519 Phase II Venetoclax Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax Recruiting
NCT04434196 Phase I CC-99282 + Obinutuzumab A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Not yet recruiting
NCT04458610 Phase II Rituximab + Zanubrutinib BTK Inhibitor Zanubrutinib (BGB-3111) in Combination With Rituximab for Previously Untreated Patient Recruiting